Recorded: 04 Jun 2001
I shared an office with Terri, because when I came [to Cold Spring Harbor Laboratory] they didn’t put me in the general postdoc office because it was full. I actually shared Terri’s office with her. She was a very heavy smoker in those days, so, I probably could sue her for passive smoking, but, we spent a lot of time talking. I mean she was—even at that stage—she was moving to some extent into the more organizational parts of running the lab and making sure things were done. I mean looking back on it we were so insulated. [After] running a lab myself and realizing what you have to do, and all these grants are getting written, and stuff has happened—Joe [Sambrook] was hugely hard working. A brilliant writer, he would do a lot of things to make the lab run that people weren’t aware of, I think. There was always money, there were always reagents. We didn’t see that hard side that much.
David Lane, immunologist, is the Director of the Cancer Research UK Transformation Research Group at the University of Dundee, Department of Surgery and Molecular Oncology at the Ninewells Hospital and Medical School in Dundee, Scotland. Lane founded the Department of Surgery and Oncology in the University’s Medical School with Alfred Cucheiri, one of the pioneers in minimal access ("keyhole") surgery. Currently on leave from the University of Dundee, he the Executive Director of the IMCB in Singapore. Lane is also the founder and Chairman of the Scientific Advisory Board of Cyclacel, a Dundee based biotechnology company now listed on the NASDAQ. Shortly after receiving his Ph.D., he was recruited by Joe Sambrook to work at Cold Spring Harbor Laboratory with the Tumor Virus Group in the 70’s, where he also completed one of his books on antibodies. In 2000, Lane was knighted by Queen Elizabeth of England for his many contributions to science. He is a Fellow of the Royal Society of London, the Academy of Medical Sciences, and the University College London.